Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

ACUTE LYMPHOBLASTIC LEUKEMIA

Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood. 2002;100:420–6.

    CAS  Article  Google Scholar 

  2. 2.

    Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14.

    CAS  Article  Google Scholar 

  3. 3.

    Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470–8.

    CAS  Article  Google Scholar 

  4. 4.

    Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia. 2013;27:1497–503.

    CAS  Article  Google Scholar 

  5. 5.

    Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N. Engl J Med. 1998;338:1663–71.

    CAS  Article  Google Scholar 

  6. 6.

    Schaison G, Auclerc MF, Baruchel A, Leblanc T, Leverger G. [Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93]. Bull Acad Natl Med. 2001;185:149–60. discussion 60–2

    CAS  PubMed  Google Scholar 

  7. 7.

    Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077–84.

    CAS  Article  Google Scholar 

  8. 8.

    Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548–55.

    CAS  Article  Google Scholar 

  9. 9.

    Steinherz PG, Seibel NL, Sather H, Ji L, Xu X, Devidas M, et al. Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group. Leukemia. 2019.

  10. 10.

    Toft N, Birgens H, Abrahamsson J, Bernell P, Griskevicius L, Hallbook H, et al. Risk group assignment differs for children and adults 1–45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol. 2013;90:404–12.

    Article  Google Scholar 

  11. 11.

    Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2014;15:809–18.

    Article  Google Scholar 

  12. 12.

    Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.

    Article  Google Scholar 

  13. 13.

    Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15.

    CAS  Article  Google Scholar 

  14. 14.

    Arico M, Valsecchi MG, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of dnA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol. 2008;26:283–9.

    CAS  Article  Google Scholar 

  15. 15.

    Moricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dordelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.

    Article  Google Scholar 

  16. 16.

    Moricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127:2101–12.

    CAS  Article  Google Scholar 

  17. 17.

    Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13:936–45.

    CAS  Article  Google Scholar 

  18. 18.

    Locatelli F, Valsecchi MG, Moricke A, Zimmermann M, Gruhn B, Biondi A, et al. Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. Blood. 2017;130:2146–9.

    CAS  Article  Google Scholar 

  19. 19.

    Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Moricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.

    CAS  Article  Google Scholar 

  20. 20.

    Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, et al. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019;104:986–92.

    CAS  Article  Google Scholar 

  21. 21.

    Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk b-acute lymphoblastic leukemia: A report from childrenʼs oncology group study AALL0232. J Clin Oncol. 2016;34:2380–8.

    CAS  Article  Google Scholar 

  22. 22.

    Testi AM, Attarbaschi A, Valsecchi MG, Moricke A, Cario G, Niggli F, et al. Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15–17 years: long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study. Eur J Cancer. 2019;122:61–71.

Download references

Acknowledgements

We thank all participating institutions and physicians for their support of the study. For AIEOP: this work was supported by Comitato M. L. Verga and Fondazione Tettamanti (Monza), Fondazione Città della Speranza, Associazione Italiana per la Ricerca sul Cancro (AB IG 2017 (#20564)) and Transcall2 (AB ID 189). For BFM: this work was supported by Deutsche Krebshilfe e.V., Bonn, Germany (grant 50-2698 Schr1 and grant 50-2410 Ba7), Oncosuisse/Krebsforschung, Switzerland (grant OCS 1230-02-2002), and St. Anna Kinderkrebsforschung, Austria.

Author information

Affiliations

Authors

Consortia

Contributions

M. Schrappe, V.C., G.M., A.B., F.L. and F.N. were involved in designing and planning the study. A.A., G.M., M.Z., M. Schrappe and V.C. wrote the manuscript. M. Schrappe, A.A., G.M., M.Z., P.B., E.B., G.B., A.B., G. Cario, A.C., M.K., P.L., M.L., C.L, F.L., L.N., A.M., F.N., R.P., C.P., M.C.P, C.R. and M. Suttorp were principal or co-investigators in their study groups and institutions, coordinated the national trials in their countries, provided study materials and recruited patients. G.B., G. Cazzaniga, C.F. and R.P.-G. were in charge of MRD analysis. M.Z. and M.G.V. performed the statistical analyses. M. Schrappe, M.Z., A.M., M.G.V. and V.C. oversaw data checking, pooling and reporting during the study period and analysed the data. All authors have approved the final version of the manuscript.

Corresponding author

Correspondence to Andishe Attarbaschi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Attarbaschi, A., Mann, G., Zimmermann, M. et al. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia 34, 1694–1700 (2020). https://doi.org/10.1038/s41375-019-0670-y

Download citation

Further reading

Search

Quick links